

Supplementary appendix

This appendix has been provided by the authors to supplement readers with additional information about this work.

1. Clinical symptoms and risk factors for which hospitalization is considered in confirmed COVID-19 patients

Patients where the following applies are asked to be hospitalized for monitoring and treatment. In the early stages of COVID-19, Korea mandated that all confirmed patients should be hospitalised or enter a treatment centre. Since October 2021, the concept of home treatment has been actively used to support the efficient use of available hospital beds. Since November 2021, home treatment has been widely preferred; only cases that fall under the following indications are hospitalised.

Supplementary Table 1. Clinical symptoms and risk factors for which hospitalisation is considered in confirmed COVID-19 patients

- A person aged 70 and older who is not vaccinated
- Unconsciousness after the appearance of COVID-19 symptoms
- Difficulty in breathing (in daily life)
- Fever higher than 38 °C that is not controlled by antipyretic drugs
- Diabetes that is not controlled by drug use
- A patient who needs dialysis
- Chronic lung disease, asthma, heart failure, or coronary artery disease treated with drugs after diagnosis
- A patient receiving chemotherapy or immunosuppressive drugs
- A patient with mental illness uncontrolled by drugs
- A person who spends more than 50% of the daytime in bed
- A person with severe obesity (BMI above 30)
- A pregnant woman with symptoms (abdominal pain, labour pain, vaginal bleeding, etc.)
- High-risk and severely ill children
 - Difficulty in breathing, dyspnoea, cyanosis
 - Poor oral intake and dehydration
 - Children diagnosed with chronic lung disease/heart disease/metabolic disease/ immune disorder and receiving immunosuppressants
 - Children with respiratory function disorder, secretion discharge, or high risk of aspiration

2. Severity of COVID-19


The most important factor in determining whether hospitalisation is necessary for a confirmed case is the severity of symptoms. The patients were assigned to appropriate hospitals according to the severity of COVID-19.

Supplementary Table 2. Disease severity classification for COVID-19

Level	Definition	Severity
1	No limit of activity	Mild or less
2	Limited activity but no O ₂ needed	
3	O ₂ with nasal prong	Moderate
4	O ₂ with facial mask	
5	Non-invasive ventilation/high-flow O ₂	Severe
6	Invasive ventilation	
7	Multi-organ failure/ECMO/CRRT	
8	Death	Death

3. Percentage of omicron variant infection cases in South Korea

Supplementary Figure 1. Percentage of omicron variant infection cases in South Korea



In contrast to other countries, in which the omicron variant became the dominant strain within 4–6 weeks, it took about nine weeks to become the dominant strain since the first notification of the omicron variant on 24 November 2021 due to quarantine and isolation guidelines in South Korea. (Source: Korea Disease Control and Prevention Agency press release, 14 January 2022)

4. Laboratory procedures

4.1. Sample preparation

Serum samples for antibody measurement were collected on the day of admission and stored at -20 °C until analysis was performed. Frozen samples were thawed before antibody determination.

4.2. Anti-SARS-CoV-2 assays

Antibodies against the S protein, the target of vaccines, were analysed using the Elecsys AntiSARS-CoV-2 S assay (Roche Diagnostics, Mannheim, Germany), an electrochemiluminescence immunoassay that detects antibodies, including IgG, to the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein on the Cobas e801 module (Roche Diagnostics, Mannheim, Germany), with a measuring range from 0.4 U/mL to 250 U/mL (up to 25,000 U/mL with onboard 1:100 dilution). Values ≥ 0.8 U/mL were considered positive. All samples were processed according to the manufacturer's instructions with specified controls and calibrators by trained laboratory staff.

4.3. RNA Extraction and SARS-CoV-2 and Variants Detection

The MagNA Pure 96 System (Roche Diagnostics, Mannheim, Germany) was used to extract RNA from nasopharyngeal swabs in viral transport media, according to the manufacturer's instructions. The extracted RNA was then subjected to the Allplex SARS-CoV-2 Assay, which targets four genes in a single tube (E, N, RdRp, and S genes) to detect SARS-CoV-2 infection, according to the manufacturer's instructions. PCR amplification was performed using the CFX96 real-time PCR detection system (Bio-Rad Laboratories, Hercules, CA, USA).

For SARS-CoV-2 variant detection, Novaplex SARS-CoV-2 Variants I, II, IV, and VII assays

(Seegene, Seoul, South Korea) were used in combination, according to the manufacturer's instructions. Briefly, 5 μ L of the nucleic acid extract was mixed with 5 μ L of primers and probes, 5 μ L of buffer, and 5 μ L of the enzyme contained in each kit. Plates were run on CFX96 with the following protocol: a reverse transcription step was initially performed at 50 °C for 20 min, then a denaturation step 95 °C for 15 min, initial cycling for 3 steps at 95 °C for 10 s, 60 °C for 40 s, and 72 °C for 20 s were performed. Finally, 42 rapid cycles at 95 °C for 10 s, 60 °C for 15 s, and 72 °C for 10 s were executed and fluorescence reads were recorded at 60 °C and 72 °C. Results interpretation and data analysis were performed using Seegene viewer. Detectable target mutations for each kit are as follows: 69/70del, E484K, and N501Y for the Variants I; W152C K417N, K417T and L452R for the Variants II; K417N, L452R, and P681R for the Variants IV; 69/70del, E484A, and N501Y for the Variants VII Assay. The target and detectable variants for each assay are shown in the Supplementary Table.

5. Supplementary Tables and Figure legends

Supplementary Table 3. Clinical characteristics of patients with SARS-CoV-2 breakthrough infection according to variant type

Variable	Delta variant (<i>n</i> = 43)	Omicron variant (<i>n</i> = 68)	<i>p</i> -value
Demographic data			
Age (years)	60.7 ± 14.9	53.2 ± 21.2	0.032
Female, n (%)	18 (41.9%)	37 (54.4%)	0.197
Body weight index (kg/m ²)	24.3 ± 3.4	23.3 ± 3.8	0.143
Immunocompromised, n (%)	6 (14.0%)	7 (10.3%)	0.559
Charlson comorbidity index ≥ 3, n (%)	24 (55.8%)	27 (39.7%)	0.097
Asymptomatic at diagnosis, n (%)	9 (20.9%)	2 (2.9%)	0.003 ^a
Time since the completion of vaccination (days)	93 ± 59.4	85.6 ± 48.0	0.431
Laboratory data (worst results during hospitalisation)			
CRP (mg/L)	52.0 ± 79.4	13.9 ± 20.3	0.003
Lymphocyte (10 ³ cells/uL)	1.3 ± 0.7	1.41 ± 0.5	0.288
IL-6 (pg/mL)	44.9 ± 96.6	8.8 ± 12.6	0.047
D-dimer (mcgFEU/mL)	0.8 ± 1.6	0.6 ± 1.1	0.328
Clinical courses during hospitalisation			
Fever (BT ≥ 37.5 °C), n (%)	26 (60.5%)	41 (60.3%)	0.986
Time to defervescence (days)	3.9 ± 2.2	3.3 ± 1.8	0.278

Pneumonia [†] , n (%)	21 (48.8%)	7 (10.3%)	<0.001
Hypoxia (SpO ₂ < 94 %), n (%)	9 (20.9%)	2 (2.9%)	0.003 ^a
Duration of oxygenation (days)	7 ± 2.7	4.0 ± 0.0	0.374
Treatments			
High flow, n (%)	2 (4.7%)	0 (0.0%)	0.148 ^a
Regdanvimab, n (%)	3 (7.0%)	2 (2.9%)	0.374 ^a
Remdesivir, n (%)	9 (20.9%)	5 (7.4%)	0.036
Dexamethasone, n (%)	12 (27.9%)	7 (10.3%)	0.016
Antimicrobial agents, n (%)	16 (37.2%)	10 (14.7%)	0.006

Data are expressed as mean ± standard deviation or number with percentages. Abbreviations: BMI, body mass index; CCI, Charlson comorbidity index; CRP, C-reactive protein; IL, interleukin; BT, body temperature; SpO₂, percutaneous oxygen saturation; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2
^a*p*-value was calculated by Fisher's Exact Test.

[†]Presence of pneumonia was determined using chest radiography.

Supplementary Table 4. Clinical characteristics of patients with delta and omicron variant infection according to vaccination status

Variable	Unvaccinated (n = 50)	Vaccinated (n = 111)	p-value
Demographic data			
Age (years)	50.9 ± 17.7	56.1 ± 19.3	0.108
Female, n (%)	30 (60.0%)	55 (49.6%)	0.219
Body weight index (kg/m ²)	23.5 ± 4.4	23.7 ± 3.7	0.806
Immunocompromised, n (%)	10 (20.0%)	13 (11.7%)	0.164
Charlson comorbidity index ≥ 3, n (%)	16 (32.0%)	51 (46.0%)	0.097
Asymptomatic at diagnosis, n (%)	43 (86.0%)	100 (90.1%)	0.446
Laboratory data (worst results during hospitalisation)			
CRP (mg/L)	37.1 ± 42.7	28.6 ± 54.8	0.337
Lymphocyte (10 ³ cells/uL)	1.0 ± 0.6	1.4 ± 0.6	0.002
IL-6 (pg/mL)	17.6 ± 17.6	20.7 ± 58.3	0.644
D-dimer (mcgFEU/mL)	0.7 ± 1.0	0.6 ± 1.3	0.999
Clinical courses during hospitalisation			
Fever (BT ≥ 37.5 °C), n (%)	41 (82.0%)	67 (60.4%)	0.007
Time to defervescence (days)	5.1 ± 3.3	3.5 ± 2.0	0.011
Pneumonia [†] , n (%)	28 (56.0%)	28 (25.2%)	<0.001
Hypoxia (SpO ₂ < 94 %), n (%)	13 (26.0%)	11 (9.9%)	0.008
Duration of oxygenation (days)	6.3 ± 2.9	6.5 ± 2.7	0.862
Treatments			
High flow, n (%)	2 (4.0%)	2 (1.8%)	0.589 ^a
Regdanvimab, n (%)	6 (12.0%)	5 (4.5%)	0.098 ^a

Remdesivir, n (%)	14 (28.0%)	14 (12.6%)	0.017
Dexamethasone, n (%)	21 (42%)	19 (17.1%)	<0.001
Antimicrobial agents, n (%)	22 (44%)	26 (23.4%)	0.008

Patients were classified into two groups according to vaccination status, regardless of variant type. Data are expressed as mean \pm standard deviation or number with percentages. Abbreviations: BMI, body mass index; CCI, Charlson comorbidity index; CRP, C-reactive protein; IL, interleukin; BT, body temperature; SpO₂, percutaneous oxygen saturation

^a*p*-value was calculated by Fisher's Exact Test.

[†]Presence of pneumonia was determined using chest radiography.

Supplementary Table 5. Clinical characteristics of patients with breakthrough infection caused by delta and omicron variant according to booster vaccination status

Variable	Booster-unvaccinated (<i>n</i> = 64)	Booster-vaccinated (<i>n</i> = 47)	<i>p</i> -value
Demographic data			
Age (years)	49.1 ± 18.5	65.6 ± 16.1	<0.001
Female, n (%)	29 (45.3%)	26 (55.3%)	0.298
Body weight index (kg/m ²)	23.5 ± 3.5	24.0 ± 3.9	0.453
Immunocompromised, n (%)	8 (12.5%)	5 (10.7%)	0.763
Charlson comorbidity index ≥ 3, n (%)	24 (37.5%)	27 (57.5%)	0.037
Asymptomatic at diagnosis, n (%)	6 (9.4%)	5 (10.6%)	>0.999 ^a
Time since the completion of vaccination (days)	122.5 ± 39.1	42.9 ± 28.1	<0.001
Laboratory data (worst results during hospitalisation)			
CRP (mg/L)	36.3 ± 67.2	18.2 ± 28.3	0.056
Lymphocyte (10 ³ cells/uL)	1.3 ± 0.6	1.5 ± 0.6	0.064
IL-6 (pg/mL)	27.9 ± 74.5	10.6 ± 16.1	0.100
D-dimer (mcgFEU/mL)	0.8 ± 1.6	0.5 ± 0.7	0.243
Clinical courses during hospitalisation			
Fever (BT ≥ 37.5 °C), n (%)	41 (64.1%)	26 (55.3%)	0.352
Time to defervescence (days)	3.8 ± 2.3	3.1 ± 1.3	0.123
Pneumonia [†] , n (%)	19 (29.7%)	9 (19.2%)	0.207
Hypoxia (SpO ₂ < 94 %), n (%)	8 (12.5%)	3 (6.38%)	0.350 ^a
Duration of oxygenation (days)	7.8 ± 2.5	4.0 ± 0.0	0.058
Treatments			
High flow, n (%)	2 (3.1%)	0 (0.0%)	0.507 ^a

Regdanvimab, n (%)	3 (4.7%)	2 (4.3%)	>0.999 ^a
Remdesivir, n (%)	10 (15.6%)	4 (8.5%)	0.265
Dexamethasone, n (%)	15 (23.4%)	4 (8.5%)	0.039
Antimicrobial agents, n (%)	18 (28.1%)	8 (17.0%)	0.172

Patients were classified into two groups according to booster vaccination status, regardless of the variant type. Data are expressed as mean ± standard deviation or number with percentages. Abbreviations: BMI, body mass index; CCI, Charlson comorbidity index; CRP, C-reactive protein; IL, interleukin; BT, body temperature; SpO₂, percutaneous oxygen saturation

^a*p*-value was calculated by Fisher's Exact Test.

[†]Presence of pneumonia was determined using chest radiography.

Supplementary Table 6. Clinical characteristics of patients with delta variant infection according to vaccination status

Variable	Unvaccinated (<i>n</i> = 36)	Vaccinated (<i>n</i> = 43)	<i>p</i> -value
Demographic data			
Age (years)	55 ± 16.2	60.7 ± 14.9	0.111
Female, n (%)	22 (61.1%)	18 (41.9%)	0.088
Body weight index (kg/m ²)	22.6 ± 2.5	24.3 ± 3.4	0.017
Immunocompromised, n (%)	5 (13.9%)	6 (14.0%)	0.993
Charlson comorbidity index ≥ 3, n (%)	15 (41.7%)	24 (55.8%)	0.210
Asymptomatic at diagnosis, n (%)	5 (13.9%)	9 (20.9%)	0.414
Laboratory data (worst results during hospitalisation)			
CRP (mg/L)	42.2 ± 45.2	52.0 ± 60.5	0.495
Lymphocyte (10 ³ cells/uL)	0.9 ± 0.4	1.3 ± 2.2	0.004
IL-6 (pg/mL)	19.4 ± 14.9	44.9 ± 96.6	0.157
D-dimer (mcgFEU/mL)	0.7 ± 1.2	0.8 ± 1.6	0.691
Clinical courses during hospitalisation			
Fever (BT ≥ 37.5 °C), n (%)	31 (86.1%)	26 (60.5%)	0.011
Time to defervescence (days)	5.1 ± 3.2	3.9 ± 2.2	0.135
Pneumonia [†] , n (%)	23 (63.9%)	21 (48.8%)	0.180
Hypoxia (SpO ₂ < 94 %), n (%)	11 (30.6%)	9 (20.9%)	0.327
Duration of oxygenation (days)	6.5 ± 2.9	7.0 ± 2.7	0.729
Treatments			
High flow, n (%)	1 (2.8%)	2 (4.7%)	>0.999 ^a
Regdanvimab, n (%)	5 (13.9%)	3 (7.0%)	0.458 ^a

Remdesivir, n (%)	10 (27.8%)	9 (20.9%)	0.478
Dexamethasone, n (%)	16 (44.4%)	12 (27.9%)	0.126
Antimicrobial agents, n (%)	17 (47.2%)	16 (37.2%)	0.369

Data are expressed as mean \pm standard deviation or number with percentages. Abbreviations: BMI, body mass index; CCI, Charlson comorbidity index; CRP, C-reactive protein; IL, interleukin; BT, body temperature; SpO₂, percutaneous oxygen saturation

^a*p*-value was calculated by Fisher's Exact Test.

[†]Presence of pneumonia was determined using chest radiography.

Supplementary Table 7. Clinical characteristics of patients with breakthrough infection caused by delta variant according to booster vaccination status

Variable	Fully vaccinated (<i>n</i> = 30)	Booster vaccinated (<i>n</i> = 13)	<i>p</i> -value
Demographic data			
Age (years)	58.4 ± 15.7	65.9 ± 11.7	0.135
Female, <i>n</i> (%)	10 (33.3%)	8 (61.5%)	0.085
Body weight index (kg/m ²)	24.3 ± 3.3	24.4 ± 3.9	0.960
Immunocompromised, <i>n</i> (%)	4 (13.3%)	2 (15.4%)	>0.999
Charlson comorbidity index ≥ 3, <i>n</i> (%)	18 (60.0%)	6 (46.2%)	0.401
Asymptomatic at diagnosis, <i>n</i> (%)	6 (20.0%)	3 (23.1%)	>0.999 ^a
Time since the completion of vaccination (days)	121.9 ± 47.3	28.9 ± 19.7	<0.001
Laboratory data (worst results during hospitalisation)			
CRP (mg/L)	63.5 ± 90.0	25.6 ± 37.4	0.058
Lymphocyte (10 ³ cells/uL)	1.2 ± 0.7	1.4 ± 0.7	0.302
IL-6 (pg/mL)	57.6 ± 112.2	13.7 ± 20.0	0.090
D-dimer (mcgFEU/mL)	1.0 ± 1.9	0.6 ± 0.7	0.360
Clinical courses during hospitalisation			
Fever (BT ≥ 37.5 °C), <i>n</i> (%)	20 (66.7%)	6 (46.2%)	0.206
Time to defervescence (days)	4.1 ± 2.5	3.2 ± 1.2	0.380
Pneumonia [†] , <i>n</i> (%)	17 (56.7%)	4 (30.8%)	0.119
Hypoxia (SpO ₂ < 94 %), <i>n</i> (%)	8 (26.7%)	1 (7.7%)	0.237 ^a
Duration of oxygenation (days)	7.8 ± 2.5	4.0 ± 0.0	0.272
Treatments			
High flow, <i>n</i> (%)	2 (6.7%)	0 (0.0%)	>0.999 ^a

Regdanvimab, n (%)	3 (10.0%)	0 (0.0%)	0.542 ^a
Remdesivir, n (%)	8 (26.7%)	1 (7.7%)	0.237 ^a
Dexamethasone, n (%)	11 (36.7%)	1 (7.7%)	0.070 ^a
Antimicrobial agents, n (%)	14 (46.7%)	2 (15.4%)	0.086 ^a

Patients were classified into two groups according to their booster vaccination status. Data are expressed as mean \pm standard deviation or number with percentages. Abbreviations: BMI, body mass index; CCI, Charlson comorbidity index; CRP, C-reactive protein; IL, interleukin; BT, body temperature; SpO₂, percutaneous oxygen saturation

^a*p*-value was calculated by Fisher's Exact Test.

[†]Presence of pneumonia was determined using chest radiography.

Supplementary Table 8. Clinical characteristics of patients with omicron variant infection according to vaccination status

Variable	Unvaccinated (n = 14)	Vaccinated (n = 68)	p-value
Demographic data			
Age (years)	40.4 ± 17.5	53.2 ± 21.2	0.037
Female, n (%)	8 (57.1%)	37 (54.4%)	0.852
Body weight index (kg/m ²)	25.8 ± 6.9	23.3 ± 3.8	0.209
Immunocompromised, n (%)	5 (35.7%)	7 (10.3%)	0.028 ^a
Charlson comorbidity index ≥ 3, n (%)	1 (7.1%)	27 (39.7%)	0.028 ^a
Asymptomatic at diagnosis, n (%)	2 (14.3%)	2 (2.9%)	0.133 ^a
Laboratory data (worst results during hospitalisation)			
CRP (mg/L)	23.8 ± 33.6	13.9 ± 20.3	0.302
Lymphocyte (10 ³ cells/uL)	1.4 ± 0.7	1.4 ± 0.5	0.952
IL-6 (pg/mL)	14.4 ± 22.0	8.8 ± 12.6	0.397
D-dimer (mcgFEU/mL)	0.6 ± 0.5	0.6 ± 1.1	0.964
Clinical courses during hospitalisation			
Fever (BT ≥ 37.5 °C), n (%)	10 (71.4%)	41 (60.3%)	0.434
Time to defervescence (days)	5.1 ± 3.9	3.3 ± 1.8	0.266
Pneumonia [†] , n (%)	5 (35.7%)	7 (10.3%)	0.028 ^a
Hypoxia (SpO ₂ < 94 %), n (%)	2 (14.3%)	2 (2.9%)	0.133 ^a
Duration of oxygenation (days)	4.0 ± 0.0	4.0 ± 0.0	NA
Treatments			
High flow, n (%)	1 (7.1%)	0 (0.0%)	0.171 ^a
Regdanvimab, n (%)	1 (7.1%)	2 (2.9%)	0.434 ^a

Remdesivir, n (%)	4 (28.6%)	5 (7.4%)	0.042 ^a
Dexamethasone, n (%)	5 (35.7%)	7 (10.3%)	0.028 ^a
Antimicrobial agents , n (%)	5 (35.7%)	10 (14.7%)	0.121

Data are expressed as mean \pm standard deviation or number with percentages. BMI, body mass index; CCI, Charlson comorbidity index; CRP, C-reactive protein; IL, interleukin; BT, body temperature; SpO₂, saturation of percutaneous oxygen; NA, not applicable

^a*p*-value was calculated by Fisher's Exact Test.

[†]Presence of pneumonia was determined using chest radiography.

Supplementary Table 9. Clinical characteristics of patients with breakthrough infection caused by omicron variant according to booster vaccination status

Variable	Fully vaccinated (<i>n</i> = 34)	Booster vaccinated (<i>n</i> = 34)	<i>p</i> -value
Demographic data			
Age (years)	40.9 ± 17.1	65.5 ± 17.7	<0.001
Female, n (%)	19 (55.9%)	18 (52.9%)	0.808
Body weight index (kg/m ²)	22.7 ± 3.6	23.8 ± 3.9	0.218
Immunocompromised, n (%)	4 (11.8%)	3 (8.8%)	>0.999 ^a
Charlson comorbidity index ≥ 3, n (%)	6 (17.7%)	21 (61.8%)	<0.001
Asymptomatic at diagnosis, n (%)	0 (0.0%)	2 (5.9%)	0.492 ^a
Time since the completion of vaccination (days)	123.0 ± 30.9	48.3 ± 29.3	<0.001
Laboratory data (worst results during hospitalisation)			
CRP (mg/L)	12.4 ± 15.9	15.4 ± 24.1	0.553
Lymphocyte (10 ³ cells/uL)	1.3 ± 0.5	1.5 ± 0.5	0.185
IL-6 (pg/mL)	8.1 ± 10.2	9.6 ± 15.0	0.636
D-dimer (mcgFEU/mL)	0.6 ± 1.4	0.5 ± 0.7	0.582
Clinical courses during hospitalisation			
Fever (BT ≥ 37.5 °C), n (%)	21 (61.8%)	20 (58.8%)	0.804
Time to defervescence (days)	3.5 ± 2.2	3.1 ± 1.3	0.416
Pneumonia [†] , n (%)	2 (5.9%)	5 (14.7%)	0.428 ^a
Hypoxia (SpO ₂ < 94 %), n (%)	0 (0.0%)	2 (5.9%)	0.493 ^a
Duration of oxygenation (days)	0.0 ± 0.0	4.0 ± 0.0	NA
Treatments			
High flow, n (%)	0 (0.0%)	0 (0.0%)	NA

Regdanvimab, n (%)	0 (0.0%)	2 (5.9%)	0.493 ^a
Remdesivir, n (%)	2 (5.9%)	3 (8.8%)	>0.999 ^a
Dexamethasone, n (%)	4 (11.8%)	3 (8.8%)	>0.999 ^a
Antimicrobial agents, n (%)	4 (11.8%)	6 (17.7%)	0.494

Patients were classified into two groups according to their booster vaccination status. Data are expressed as mean ± standard deviation or number with percentages. BMI, body mass index; CCI, Charlson comorbidity index; CRP, C-reactive protein; IL, interleukin; BT, body temperature; SpO₂, saturation of percutaneous oxygen; NA, not applicable

^a*p*-value was calculated by Fisher's Exact Test.

[†]Presence of pneumonia was determined using chest radiography.

Supplementary Table 10. Geometric mean titres of antibodies in patients with breakthrough infection caused by delta and omicron variant

	Antibody titre (U/mL)	<i>p</i> -value
Fever		<0.001
BT ≥ 37.5 °C	1201.5 (715.1-2018.5)	
BT < 37.5 °C	4610.4 (3155.5-6736.2)	
Hypoxia		0.017
SpO ₂ ≥ 94 %	98.8 (7.9-1232.2)	
SpO ₂ < 94 %	2674.5 (1988.0-3598.0)	
Pneumonia [†]		0.042
With pneumonia	774.1 (235.6-2543.3)	
Without pneumonia	2761.0 (2063.6-3694.2)	
CRP elevation		0.015
CRP > 8 mg/L	1335.1 (735.8-2422.3)	
CRP ≤ 8 mg/L	3216.0 (2182.4-4739.1)	
Lymphopenia		0.035
Lymphocyte < 1,100 cell/uL	1032.2 (420.4-2534.7)	
Lymphocyte ≤ 1,100 cell/uL	2855.5 (2106.2-3871.5)	

The antibody level was expressed as the geometric mean (95% confidential interval). Abbreviations: BT, body temperature; SpO₂, percutaneous oxygen saturation; CRP, C-reactive protein; CCI, Charlson comorbidity index.

[†]Presence of pneumonia was determined using chest radiography.

Figure legends


Supplementary figure 2. Association of antibody levels and specific symptoms and signs during hospitalisation in fully vaccinated patients with delta or omicron variant breakthrough infection (sensitivity analyses using 3-day threshold)

Antibody levels for each variable representing the clinical course are described as box plots of median and 95% CI in 80 patients with available antibody levels.


Supplementary figure 3. Association of antibody levels and specific symptoms and signs during hospitalisation in fully vaccinated patients with delta or omicron variant breakthrough infection (sensitivity analyses using 5-day threshold)

Antibody levels for each variable representing the clinical course are described as box plots of median and 95% CI in 100 patients with available antibody levels.


A. Delta and omicron



B. Delta




C. Omicron




Supplementary Figure 2.


A. Delta and omicron



B. Delta



C. Omicron



Supplementary Figure 3.